Enzyme Replacement Therapy in Hypophosphatasia
J Coll Physicians Surg Pak
; 28(9): S198-S200, 2018 09.
Article
en En
| MEDLINE
| ID: mdl-30173697
ABSTRACT
Hypophosphatasia (HPP) is associated with significant morbidity and mortality in pediatric patients. The disease also imposes a high disease-burden in adult-onset HPP. Asfotase alfa (AA) is the first-in-class, bone-targeted, enzyme- replacement therapy designated to reverse the skeletal mineralisation defects in HPP. A male newborn presented with extreme fontanel gap and respiratory distress. He was diagnosed with perinatal lethal HPP thus AA treatment was started. Serum alkaline phosphatase (ALP) levels increased as high as 12,700 U/L during treatment. Any side effect related to AA was not observed. AA may be a valuable emerging therapy for the treatment of HPP.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Proteínas Recombinantes de Fusión
/
Inmunoglobulina G
/
Fosfatasa Alcalina
/
Terapia de Reemplazo Enzimático
/
Hipofosfatasia
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
/
Male
/
Newborn
Idioma:
En
Revista:
J Coll Physicians Surg Pak
Asunto de la revista:
MEDICINA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Turquía